Mutation Load Offers Biomarker in SCLC.
Mutation Load Offers Biomarker in SCLC.
复制标题
突变负荷为 SCLC 提供生物标志物。
DOI：
10.1158/2159-8290.cd-nb2017-154
复制
发表时间：
2017
期刊：
影响因子：
28.2
通讯作者：
O. Yonemitsu
中科院分区：
文献类型：
--
作者：
K. Horita;Y. Sakurai;M. Nagasawa;O. Yonemitsu
肿瘤突变负荷为小细胞肺癌患者提供了一个有前途的预测生物标志物。在世界肺癌大会上发表的一项探索性分析表明，与突变负荷低的患者相比，癌细胞中有大量突变的患者更有可能对单一检查点抑制剂或它们的组合产生反应，并且持续时间更长。
Tumor mutation burden offers a promising predictive biomarker for patients with small cell lung cancer. An exploratory analysis presented at the World Conference on Lung Cancer showed that the patients with large numbers of mutations in their cancer cells were more likely to respond-and for a longer time-to a single checkpoint inhibitor or a combination of them than those with a low mutation load.